Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.47 |
| ▸ | RAB9A | P51151 | 9/20 | 0.47 |
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216192 | 0.84 | PTGDR2 (0.46) | SMN1; SMN2PTGDR2MAPTTP53ALDH1A1 | |
| SCHEMBL407427 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2PTGDR2MAPTTP53KMT2A | |
| SCHEMBL214943 | 0.81 | SCD (0.51) | KMT2ASCD | |
| SCHEMBL216751 | 0.77 | SLC5A2 (0.40) | SMN1; SMN2PTGDR2MAPTTP53ALDH1A1 | |
| SCHEMBL215875 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9AHPGDCYP1A2CYP2C9 | |
| SCHEMBL406980 | 0.76 | SLC5A2 (0.43) | SMN1; SMN2CYP1A2CYP2C9CYP2C19MAPT | |
| SCHEMBL215073 | 0.75 | PTGDR2 (0.43) | SMN1; SMN2CYP1A2CYP2C9CYP2C19PTGDR2 | |
| SCHEMBL10476873 | 0.74 | RAB9A (0.80) | SMN1; SMN2RAB9ANPC1HPGDCYP1A2 | |
| SCHEMBL2735997 | 0.74 | IKBKB (0.48) | SMN1; SMN2CYP1A2CYP2C9CYP2C19PTGDR2 | |
| SCHEMBL216748 | 0.73 | EGLN1 (0.44) | CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | claimed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | claimed |
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8088792-B2 | Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2268637-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009137201-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065227-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | SMN1; SMN2 3270/4885RAB9A 2518/4885NPC1 541/4885 |
| US-20090253738-A1 | TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, FASN | SMN1; SMN2 3270/4885RAB9A 2518/4885NPC1 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.